Kening Bio Secures Nearly RMB 100 Million in Pre-A Financing Led by LongPan Investment

Investment Circle (ID: pedaily2012) April 1 News: Pleryon Biopharmaceuticals (Shenzhen) Co., Ltd. (hereinafter referred to as:Pleryon")" announced completionNearly 100 million yuanPre-Series AFinancing. This round of financing was led byLapamCapitalLeading investment,Kaitai CapitalAnd existing shareholdersQingkeVenture CapitalFollow-up Investment.

PleryonDedicated to developing innovative drugs based on advanced drug delivery systems. The core team members of the company have previously worked at renowned universities and multinational pharmaceutical companies both domestically and overseas, possessing over 20 years of R&D experience in innovation and clinical translation within the field of drug delivery. The importance of drug delivery systems has been fully demonstrated over the past two years. Pleryon adopts a multidisciplinary approach and multi-platform strategy to regulate drugs on both temporal and spatial scales. It has developed platforms including a drug sustained-release platform based on micro-pore size control, a polymer drug platform based on modular synthesis, and a nucleic acid delivery platform based on modular non-natural oligomers. This round of financing will support Pleryon's preclinical development of its existing innovative pipelines in ophthalmology, orthopedics, and more. Additionally, it will accelerate the construction of subsequent R&D pipelines based on its technological platforms.

Dr. Yu Yu, Founder of PleryonStated: "Pleryon has believed from its inception that drug delivery would become a crucial direction for drug innovation. We are highly honored to gain recognition from early biopharmaceutical investors like LapamCapital and Hangzhou Kaitai Capital Management Ltd. We will take this opportunity to accelerate the advancement of our pipeline and further enhance the company’s structure and team."

Mr. Yu Zhihua, Founding Partner of LapamCapitalSaid: "The drug delivery system is a very promising direction for innovative drug research and development. Pleryon, based on the laboratory research results of its core founding team, has diversified platforms and good product pipeline scalability, with huge market potential. We look forward to Pleryon's products being applied in clinical settings as soon as possible to benefit more patients!"

This article is sourced from Pedaily, original text: https://news.pedaily.cn/202204/489353.shtml